The Umeå Biotech Incubator (UBI) case RegenCura is developing a novel scaffold material with superior osteogenic properties compared to current commercial alternatives. The product targets more than two million patients annually who require dental surgery due to disease or injury.
With substantial in vitro testing since 2020, the scaffold material has demonstrated promising osteoinductive properties when using clinically isolated mesenchymal stem cells (MSCs).
Responsible for synthesis work
To strengthen its capabilities and prepare for the next development phase, RegenCura has recruited Björn Greijer as chemist, responsible for synthesis work at the UBI lab in Umeå. Björn earned his PhD in 2024 at the Department of Molecular Sciences at SLU in Uppsala, where he specialized in nanoparticle–protein interactions.
At RegenCura, he will contribute to the development of the company’s bone substitute material for maxillofacial surgery and prepare for in vivo studies and the scale-up of material synthesis.
Perfect fit for the mission
Lars Österlund, co-project owner of RegenCura, comments:
“We are pleased to welcome Björn to the team. His expertise in molecular sciences and synthesis is a perfect fit for our mission to bring a safe and effective bone substitute to market. With his contribution, we are well-positioned to advance our regulatory development and take the next important steps towards clinical application.”